Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2018

Summary of Computation of Company's Basic and Diluted Net Loss per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Numerator:
Net loss, basic and diluted	$	(10,237	)	$	(1,418	)	$	(33,824	)	$	(4,344	)
Net loss	$	(10,237	)	$	(1,418	)	$	(33,824	)	$	(4,344	)
Denominator:
Shares issued in computing net loss per share, basic and diluted		481,613			451,550			476,023			444,594
Net loss per share, basic and diluted	$	(21.26	)	$	(3.14	)	$	(71.06	)	$	(9.77	)

Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods ended September 30, 2018 and 2017, because including them would have been antidilutive:

	As of September 30,
	2018		2017
Redeemable convertible preferred stock		16,028,462		5,063,404
Options to purchase common stock		3,383,756		840,160
Warrants to purchase redeemable convertible preferred stock		117,400		93,527
Warrants to purchase common stock		942		1,099
Early exercised shares of common stock		–		5,914
Total		19,530,560		6,004,104